WO2024214083 - USE OF IMMUNOMODULATION METHODS IN COMBINATION WITH CYTOKINE FUSIONS FOR DISEASE TREATMENT
National phase entry is expected:
Publication Number
WO/2024/214083
Publication Date
17.10.2024
International Application No.
PCT/IB2024/053637
International Filing Date
13.04.2024
Title **
[English]
USE OF IMMUNOMODULATION METHODS IN COMBINATION WITH CYTOKINE FUSIONS FOR DISEASE TREATMENT
[French]
UTILISATION DE MÉTHODES D'IMMUNOMODULATION EN COMBINAISON AVEC DES FUSIONS DE CYTOKINES POUR LE TRAITEMENT DE MALADIES
Applicants **
MEDICENNA THERAPEUTICS INC.
700-2 Bloor Street West
Toronto, Ontario M4W 3E2, CA
Inventors
MERCHANT, Fahar
202-1258 Richards Street
Vancouver, British Columbia V6B 1S2, CA
Priority Data
63/496,364
14.04.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CIPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2230 | |
| EPO | Filing, Examination | 15136 | |
| Japan | Filing | 530 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 6285 |
Total: 24756 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided herein are methods of treating a cancer comprising administering: a) an IL-4 receptor targeted cargo protein or an IL-13 receptor targeted cargo protein; and b) immunomodulatory agent (e.g., an IL-2 mutein or IL-2 mutein fusion protein described herein). Such combination therapies are particularly useful for the treatment of cancers that overexpress IL-4R or IL-13Rα2. Also provided herein are composition for use with the subject methods. Aspects of the methods and compositions are further detailed below.[French]
L'invention concerne des méthodes de traitement d'un cancer comprenant l'administration : a) d'une protéine cargo ciblée sur un récepteur d'IL-4 ou d'une protéine cargo ciblée sur un récepteur d'IL-13 ; et b) d'un agent immunomodulateur (par exemple, une mutéine d'IL-2 ou une protéine de fusion de mutéine d'IL-2 décrite ici). De telles polythérapies sont particulièrement utiles pour le traitement de cancers qui surexpriment IL-4R ou IL-13Rα2. L'invention concerne également une composition destinée à être utilisée avec les méthodes de l'invention. Des aspects des méthodes et des compositions sont en outre détaillés ci-dessous.